Clinical trial
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable…
NCT00461708 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00461708 |
|---|---|
| Title | A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival |
| Official title | An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Gemcitabine |
| Enrollment | 153 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Apr 18, 2007 |
| Last update posted | Oct 15, 2015 |
| Countries | Spain |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: